公开(公告)号：US10722476B2

公开(公告)日：2020-07-28

申请号：US15912103

申请日：2018-03-05

Applicant: Intelgenx Corp.

Inventor： Horst G. Zerbe ,  Rodolphe Obeid ,  Justin W. Conway ,  Nadine Paiement ,  Ludwig Aigner

IPC: A61K9/70 ,  A61K9/00 ,  A61K31/381 ,  A61K31/404 ,  A61K31/47

Abstract: Disclosed is a device and method for treating a neurodegenerative disease or condition associated with neuroinflammation induced by a leukotriene. The device is a film unit dosage form having a film layer and a safe and effective amount of a leukotriene receptor antagonist or leukotriene synthesis inhibitor. The device is configured and formulated to achieve transmucosal and/or enteral delivery of the leukotriene receptor antagonist or leukotriene synthesis inhibitor. The method includes transmucosally and/or enterally delivering to an animal in need of treatment, a safe and effective amount of a leukotriene blocker capable of crossing the blood-brain barrier.

公开(公告)号：US20200101008A1

公开(公告)日：2020-04-02

申请号：US16146516

申请日：2018-09-28

Applicant: Intelgenx Corp.

Inventor： Nadine Paiement ,  Rodolphe Obeid ,  Justin W. Conway ,  Billal Tir

IPC: A61K9/00 ,  A61K31/4985 ,  A61K47/38

Abstract: An oral film dosage form includes a high viscosity polymer in an amount of from 1% to 5% by dry weight to reduce, modulate and/or control Cmax of an active agent. The high viscosity polymer has a viscosity of from 100 cps to 500 cps as determined at 2% concentration in water by weight at 25° C. using a Brookfield LVF viscometer with spindle no. 2 at 60 rpm

公开(公告)号：US10272038B2

公开(公告)日：2019-04-30

申请号：US15588897

申请日：2017-05-08

Applicant: Intelgenx Corp.

Inventor： Rodolphe Obeid ,  Nadine Paiement

IPC: A61K47/32 ,  A61K9/00 ,  A61K45/06 ,  A61K47/34

Abstract: An orally administered dosage form that facilitates delivery of an agent locally in the buccal cavity for a sustained period of time includes mucoadhesive particles that are made of at least a mucoadhesive material combined with the agent, and which are dispersed in a disintegrating film. The dosage form is capable of delivering an agent to a patient at the desired oral mucosa site over an extended period of time while reducing patient discomfort or annoyance associated with conventional sustained release mucoadhesive films that must reside on the oral mucosa during the period of sustained release.

公开(公告)号：US20180078549A1

公开(公告)日：2018-03-22

申请号：US15822734

申请日：2017-11-27

Applicant: Intelgenx Corp.

Inventor： Horst G. Zerbe ,  Nadine Paiement ,  Angela Angusti ,  Cormac Long

IPC: A61K31/4985 ,  A61K9/00

CPC classification number: A61K31/4985 ,  A61K9/006

Abstract: Improved pharmaceutical solid oral dosage forms for the buccal and/or sublingual delivery of Tadalafil. The improved delivery systems for solubilizing and stabilizing pharmaceutically active ingredients exhibit enhanced methods of preparation by the use improved solubilization systems which can maintain the Tadalafil in a buccal and/or sublingual oral dosage form or a polymeric film matrix that provides improved bioavailability and/or absorption of Tadalafil.

公开(公告)号：US09301948B2

公开(公告)日：2016-04-05

申请号：US14447071

申请日：2014-07-30

Applicant: IntelGenx Corp.

Inventor： Horst G. Zerbe ,  Angela Angusti ,  Nadine Paiement

IPC: A61K31/4196 ,  A61K47/02 ,  A61K47/32 ,  A61K47/38 ,  A61K9/00 ,  A61K31/422 ,  A61K31/473 ,  A61K31/5513 ,  A61K31/5517

CPC classification number: A61K31/4196 ,  A61K9/0056 ,  A61K9/006 ,  A61K31/422 ,  A61K31/473 ,  A61K31/5513 ,  A61K31/5517 ,  A61K47/02 ,  A61K47/32 ,  A61K47/38

Abstract: An instantly wettable and rapidly disintegrating oral film dosage form without a surfactant and without a polyalcohol was achieved by combining at least one water soluble polymer that is not a copolymer of vinylpyrrolidone, at least one active agent, a copolymer of vinylpyrrolidone and titanium dioxide. In certain embodiments, the film comprises hydroxypropyl cellulose or a combination of hydroxypropyl cellulose and a polymer or copolymer of vinylpyrrolidone or a substituted vinylpyrrolidone as the water soluble polymer(s). A plasticizer, and optional additives selected from synthetic sweeteners, natural sweeteners, flavorants, antioxidants, colorants, and opacifiers, can be added to the disclosed film oral dosage forms.

Abstract translation: 通过组合不是乙烯基吡咯烷酮，至少一种活性剂，乙烯基吡咯烷酮和二氧化钛的共聚物的共聚物的至少一种水溶性聚合物，实现了无表面活性剂和不含多元醇的立即可湿性和快速崩解的口腔膜剂型。 在某些实施方案中，该膜包含羟丙基纤维素或羟丙基纤维素与乙烯基吡咯烷酮或取代的乙烯基吡咯烷酮的聚合物或共聚物作为水溶性聚合物的组合。 可以向所公开的膜口服剂型中加入增塑剂和选自合成甜味剂，天然甜味剂，调味剂，抗氧化剂，着色剂和遮光剂的任选添加剂。

公开(公告)号：US20150150786A1

公开(公告)日：2015-06-04

申请号：US14554332

申请日：2014-11-26

Applicant: IntelGenx Corp.

Inventor： Rodolphe Obeid ,  Nadine Paiement

IPC: A61K9/00 ,  A61K31/155 ,  A61K31/09

CPC classification number: A61K9/006 ,  A61K31/09 ,  A61K31/155 ,  A61K47/32

Abstract: An orally administered dosage form that facilitates delivery of an agent locally in the buccal cavity for a sustained period of time includes mucoadhesive particles that are made of at least a mucoadhesive material combined with the agent, and which are dispersed in a disintegrating film. The dosage form is capable of delivering an agent to a patient at the desired oral mucosa site over an extended period of time while reducing patient discomfort or annoyance associated with conventional sustained release mucoadhesive films that must reside on the oral mucosa during the period of sustained release.

Abstract translation: 有助于在口腔中局部输送药剂持续一段时间的口服给药剂型包括粘膜粘附颗粒，其由至少粘合剂材料与药剂组合并分散在崩解膜中制成。 该剂型能够在延长的时间段内将药剂递送至期望的口腔粘膜部位的患者，同时减少在持续释放期间必须存在于口腔粘膜上的常规持续释放粘膜粘附膜所引起的患者不适或麻烦 。

公开(公告)号：US12156937B2

公开(公告)日：2024-12-03

申请号：US17952300

申请日：2022-09-25

Applicant: INTELGENX CORP.

Inventor： Nadine Paiement ,  Rodolphe Obeid ,  Justin Conway ,  Billal Tir

IPC: A61K9/00 ,  A61K31/4985 ,  A61K47/38

Abstract: An oral film dosage form includes a high viscosity polymer in an amount of from 1% to 5% by dry weight to reduce, modulate and/or control Cmax of an active agent. The high viscosity polymer has a viscosity of from 100 cps to 500 cps as determined at 2% concentration in water by weight at 25° C. using a Brookfield LVF viscometer with spindle no. 2 at 60 rpm.

公开(公告)号：US20240245603A1

公开(公告)日：2024-07-25

申请号：US18275610

申请日：2022-02-07

Applicant: INTELGENX CORP.

Inventor： Billal TIR ,  Nadine PAIEMENT

IPC: A61K9/00 ,  A61K31/439

CPC classification number: A61K9/006 ,  A61K31/439

Abstract: An oral film dosage form includes a high loading of API designed to be administered in some form to a human subject and in some other form to an animal subject.

公开(公告)号：US20240189331A1

公开(公告)日：2024-06-13

申请号：US18276918

申请日：2022-02-14

Applicant: INTELGENX CORP.

Inventor： Mobarik BILAL ,  Billal TIR ,  Nadine PAIEMENT

IPC: A61K31/675 ,  A61K9/00 ,  A61K31/4045 ,  A61K47/02 ,  A61K47/10 ,  A61K47/12 ,  A61K47/18 ,  A61K47/22 ,  A61K47/26 ,  A61K47/32 ,  A61K47/38

CPC classification number: A61K31/675 ,  A61K9/006 ,  A61K31/4045 ,  A61K47/02 ,  A61K47/10 ,  A61K47/12 ,  A61K47/186 ,  A61K47/22 ,  A61K47/26 ,  A61K47/32 ,  A61K47/38

Abstract: The present disclosure relates to oral film formulations, which provide a tryptamine active agent. The disclosure more particularly relates to oral film formulations with improved buccal absorption of tryptamine active agents. The present disclosure also relates to formulations and methods for treatment of various symptoms in a patient, such as the treatment of mental health conditions.

公开(公告)号：US20230404937A1

公开(公告)日：2023-12-21

申请号：US18208177

申请日：2023-06-09

Applicant: INTELGENX CORP.

Inventor： Billal TIR ,  Carolin MADWAR ,  Nadine PAIEMENT

IPC: A61K9/70 ,  A61K9/00 ,  A61K31/00 ,  A61K31/439 ,  A61K47/38 ,  A61K47/34 ,  A61K47/26

CPC classification number: A61K9/7007 ,  A61K9/006 ,  A61K31/658 ,  A61K47/26 ,  A61K47/38 ,  A61K47/34 ,  A61K31/439

Abstract: Oral film formulations comprising at least one hydrophobic active agent; and a polymeric matrix at least partly composed of hydrophobic or insoluble excipients, or a combination thereof, to facilitate a controlled or sustained dissolution. Wherein when the oral film formulation has an unfavorable environment for fast dissolution, it exhibits partial disintegration within 1 to 10 minutes and a sustained rate of dissolution as confirmed by a disintegration test conducted in a limited volume petri dish, and wherein the film undergoes disintegration into smaller and smaller pieces.